Examination of the rating system of peripheral neuropathy by oxaliplatin, paclitaxel using the nerve conduction survey instrument and nab paclitaxel

Not Applicable

• Conditions: Esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer; D004938/D013274/D007414/D010190

• Registration Number: JPRN-jRCT1070210108
• Lead Sponsor: Takashi Inagaki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1) We have unresectable progress, recurrence digestion ductal carcinoma (esophageal cancer, gastric cancer or colorectal cancer), pancreatic cancer.
2) We plan to receive chemotherapy including oxaliplatin or paclitaxel or nab paclitaxel.
3) There is no peripheral neuropathy before start of therapy subjectively.
4) Performance Status (PS): It is ECOG 2 or less.
5) A major organ function is kept enough.
6) An agreement is obtained in a document from patients about study entry.

Exclusion Criteria

1) We have the brain metastasis with the symptom.
2) We have diabetes mellitus inadequate control.
3) We judge the medical attendant to be inadequate as an object of this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified